The improvements seen with the antibody did not clear Celldex’s internal hurdle rate. The company said the results suggested mast cells contribute to eczema but are not its primary driver.
Barzolvolimab showed a favorable safety and tolerability profile, consistent with previously reported studies, Celldex said.

Comments (0)
No comments yet. Be the first!